Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series

Abstract

Aim: We aimed to study the clinical and pathological characteristics of liver transplant recipients with hepatocellular carcinoma recurrence.

Methods: We reviewed the data for 26 patients who had tumor recurrence after deceased donor liver transplant for hepatocellular carcinoma at the Johns Hopkins Hospital from January 2005 to December 2015.

Results: In total, 88% of recipients were males. The mean age was 59 years. On explant, poor differentiation was detected in 43%, while 73% had microvascular invasion. Overall, 62% were diagnosed to be outside of Milan criteria. Out of these, 15% met the criteria for downstaging. Twenty (77%) patients had pre-transplant alpha fetoprotein levels ≥ 20 ng/mL. In 54% of patients, the location of hepatocellular carcinoma (HCC) recurrence was extrahepatic, followed by intrahepatic in 31% and both intra- and extrahepatic in 15%. The post-transplant tumor recurrence was diagnosed at a mean of 427 days (range 34-1502). Fifty percent of HCC recurrences were diagnosed within one year following liver transplant. Twenty (77%) patients received treatment for their recurrent HCC: external radiation (n = 10), surgical resections (n = 8; brain 4, spine 2, bone 1, and Whipple surgery 1), sorafenib (n = 7), locoregional therapy (n = 5). Overall, 24 out of 26 (92%) recipients died within four years after the transplant.

Conclusion: HCC recurrence after liver transplant is infrequent. More than fifty percent of HCC recurrences following liver transplant are extrahepatic. Despite better recipient selection for liver transplant, the curative options are limited in recurrent cases and associated with extremely poor outcomes.

Keywords

Hepatocellular carcinoma / liver transplant / liver resection / locoregional therapy

References

[1] Mazzaferro V,Doci R,Pulvirenti A.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis..N Engl J Med1996;334:693-9

[2] Yao FY,Bass NM,Bacchetti P.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival..Hepatology2001;33:1394-403

[3] Mazzaferro V,Miceli R,Schiavo M.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis..Lancet Oncol2009;10:35-43

[4] Andreou A,Pascher A,Al-Abadi H.Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma..HPB (Oxford)2015;17:168-75 PMCID:PMC4299391

[5] Marshall AE,Vowler SL,Davies RJ.Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status..Liver Transpl2010;16:279-88

[6] Llovet JM,Kudo M.Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma..Liver Transpl.2011;17 Suppl 2:S67-71 PMCID:PMC3164216

[7] Fernandez-Sevilla E,Selten J,Vibert E.Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?.Liver Transpl2017;23:440-7

[8] de’Angelis N,Carra MC.Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review..World J Gastroenterol2015;21:11185-98 PMCID:PMC4607916

[9] Chok K.Management of recurrent hepatocellular carcinoma after liver transplant..World J Hepatol2015;7:1142-8 PMCID:PMC4450191

[10] Kornberg A,Tannapfel A,Thrum K.Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables..Eur J Surg Oncol2010;36:275-80

[11] Roayaie S,Sung MW,Miller CM.Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis..Liver Transpl2004;10:534-40

[12] Gurakar A,Garonzik-Wang J,Anders RA.Clinicopathological distinction of low-AFP-secreting vs. high-AFP-secreting hepatocellular carcinomas..Ann Hepatol2018;17:1052-66

[13] Guerrero-Misas M,De la Mata M.Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation..World J Hepatol2015;7:649-61 PMCID:PMC4388993

[14] Chok KS,Cheung TT,Fan ST.Late recurrence of hepatocellular carcinoma after liver transplantation..World J Surg2011;35:2058-62 PMCID:PMC3152711

[15] Zhang JA,Wong LL.Late recurrence of hepatocellular carcinoma after liver transplantation..Hepatoma Res2017;3:58-66 PMCID:PMC5619866

[16] Rubin J,Kaldas F.Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review..Exp Clin Transplant2012;10:531-43

[17] Tabrizian P,Schwartz ME.Current management of hepatocellular carcinoma..World J Gastroenterol2014;20:10223-37 PMCID:PMC4130831

[18] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[19] Cheng AL,Chen Z,Qin S.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial..Lancet Oncol2009;10:25-34

[20] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma..Nat Rev Clin Oncol2018;15:599-616

[21] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[22] Munker S.Use of checkpoint inhibitors in liver transplant recipients..United European Gastroenterol J2018;6:970-3 PMCID:PMC6137599

[23] Matter MS,Andersen JB.Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends..J Hepatol2014;60:855-65 PMCID:PMC3960348

[24] Liang W,Ling X,Kong Y.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis..Liver Transpl2012;18:62-9

[25] Mehta N,Roberts JP,Yao FY.Alpha-fetoprotein decrease from > 1,000 to < 500 ng/mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes..Hepatology2019;69:1193-205